ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 972

Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease

Hang Liu1, Cory Perugino 2, Musie Ghebremichael 1, Zachary Wallace 2, Sydney Montesi 3, John Stone 4 and Shiv Pillai 5, 1Ragon Institute of MGH, MTI and Harvard, Cambridge, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 5Ragon Institude of MGH, MIT and Harvard, Charlestown, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoantibodies and fibrosis, autoantigens, IgG4, IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The oligoclonal expansion in IgG4-related disease (IgG4-RD) of both plasmablasts and tissue-infiltrating CD4+ cytotoxic T lymphocytes, the identification of specific auto-antigens as B cell targets, and the consistent clinical responsiveness to B cell depletion all support the possibility that this disorder is an autoimmune disease in which adaptive immune responses contribute to the associated tissue fibrosis. Since 2015, four different auto-antigens have been described as potential triggers for IgG4-RD: prohibitin, annexin A11, laminin 511-E8 and galectin-3. However, validation of these findings using external patient cohorts and characterization of the relationship between these specific auto-antigens has yet to be achieved.

Methods: Autoantibody responses against prohibitin, annexin A11 and laminin 511-E8 were measured by ELISA among a clinically diverse cohort of IgG4-RD patients (n = 100). Idiopathic pulmonary fibrosis (IPF) plasma samples (n = 50) were used as a disease control and age- and sex-matched healthy donor plasma samples (n = 50) as healthy controls. We clustered our cohort into subsets of patients according to their number of autoantibody responses (no responses, 1 response, and ≥ 2 responses) and compared clinical parameters among these groups.

Results: The frequencies of IgG4 autoantibody responses against prohibitin (10%), annexin A11 (12%), and laminin 511-E8 (7%) were not significantly different from those of controls. Patients with pancreatobiliary disease did not enrich for annexin A11 or laminin 511-E8 autoantibodies. A portion of the cohort (n = 86) had been analyzed previously at our center for anti-galectin-3 antibody responses with 25 (29%) having IgG4 anti-galectin-3 antibodies. Among these 86 subjects, 32 (37%) had IgG4 antibodies to at least one of the 4 auto-antigens and 12 (14%) showed reactivity to ≥ 2 of the tested antigens. The subset of patients with ≥ 2 autoantibodies had higher total IgG1, IgG2, IgG4, and C-reactive protein levels; were more commonly hypocomplementemic; and were more likely to have visceral organ involvement.

Conclusion: Antibodies against prohibitin, annexin A11, and laminin 511-E8 were found in only a small portion of patients with IgG4-RD. A subset of IgG4-RD patients, however, had IgG4 antibodies against ≥ 2 autoantigens. Patients with antibodies against ≥ 2 autoantigens present with robust IgG subclass elevations, complement consumption, and visceral organ involvement. This broader break in immunological tolerance in IgG4-RD was associated with more severe disease. (Supported by NIH U19 AI 110495 and UM1 AI144295)


Disclosure: H. Liu, None; C. Perugino, BMS, 5, UCB, 2; M. Ghebremichael, None; Z. Wallace, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, 2, Rheumatology Research Foundation, 2; S. Montesi, Parker B. Francis Foundation, 2, Scleroderma Foundation, 2, United Therapeutics, 9; J. Stone, Genentech, 2, 5, Roche, 2, 5, Xencor, 2, 5; S. Pillai, Abpro, 6.

To cite this abstract in AMA style:

Liu H, Perugino C, Ghebremichael M, Wallace Z, Montesi S, Stone J, Pillai S. Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/disease-severity-is-linked-to-an-increase-in-autoantibody-diversity-in-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-severity-is-linked-to-an-increase-in-autoantibody-diversity-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology